A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting
toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2
dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of
the study will assess the antitumor effect of EU101 in two indications including colorectal
cancer (CRC) and non-small cell lung cancer (NSCLC).